Louisiana Department of Health Launches Innovative Payment Model with Asegua Therapeutics to Eliminate Hepatitis C in Louisiana

 Louisiana Department of Health Launches Innovative Payment Model with Asegua Therapeutics to Eliminate Hepatitis C in Louisiana

Louisiana Department of Health Launches Innovative Payment Model with Asegua Therapeutics to Eliminate Hepatitis C in Louisiana

Shots:

  • The Louisiana Department of Health signs a 5 years agreement with Asegua to implement the innovative payment model for the treatment of Hepatitis C and to improve the health of Louisiana citizens
  • The innovative payment model allows the state of Louisiana to get an unlimited amount of Asegua’s authorized generic of Epclusa (sofosbuvir/velpatasvir) to treat patients within Louisiana’s Medicaid and Department of Corrections populations and caps the State’s medication costs
  • Epclusa is a fixed-dose combination therapy indicated for the treatment of Hepatitis C genotype 1, 2, 3, 4, 5, or 6 infections with or without cirrhosis

Click here to read full press release/ article | Ref: Gilead | Image: Kratom Sciences

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post